Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT07300735

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

Led by Alexandria University · Updated on 2025-12-29

88

Participants Needed

1

Research Sites

69 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain. The study is comparing two oral medications for their effectiveness as a preventive treatment: * Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication). The core question the study is trying to answer is: * Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine? * Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?

CONDITIONS

Official Title

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 to 65 years old
  • Receiving G-CSF treatment for leukemia, lymphoma, or neutropenia prevention after autologous hematopoietic cell transplant
  • Patients may have bone pain associated with G-CSF administration or not
  • Willing to provide informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Patients with solid tumors
  • Pregnant or breastfeeding women
  • Known allergies or hypersensitivity to loratadine, diosmin-hesperidin, or filgrastim
  • Patients with pre-existing bone disorders or receiving bone modifying agents
  • Chronic use of antihistamines, diosmin-hesperidin, NSAIDs, corticosteroids, or immunosuppressants
  • Receiving medications with major interactions with loratadine, diosmin-hesperidin, or filgrastim
  • Unable to understand or provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Alexandria University Hospitals

Alexandria, Egypt, 21532

Actively Recruiting

Loading map...

Research Team

M

Mayssaa Mohamed Elsayed, M.S. Candidate

CONTACT

N

Noha AlaaEldine Hamdy, Assistant professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here